Abstract
PURPOSE To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized. METHODS We analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes. RESULTS We found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 × 10-76), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 × 10-3), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 × 10-3), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 3 1022). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age (P for trend = 2.0 × 10-3). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies (P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer. CONCLUSION These results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer risk management of PALB2 PV carriers.
Original language | English |
---|---|
Pages (from-to) | 674-685 |
Number of pages | 12 |
Journal | Journal of Clinical Oncology |
Volume | 38 |
Issue number | 7 |
DOIs | |
Publication status | Published - 1 Mar 2020 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Cancer risks associated with germline PALB2 pathogenic variants : An international study of 524 families. / Yang, Xin; Leslie, Goska; Doroszuk, Alicja; Schneider, Sandra; Allen, Jamie; Decker, Brennan; Dunning, Alison M.; Redman, James; Scarth, James; Plaskocinska, Inga; Luccarini, Craig; Shah, Mitul; Pooley, Karen; Dorling, Leila; Leei, Andrew; Adank, Muriel A.; Adlard, Julian; Aittomäki, Kristiina; Andrulis, Irene L.; Ang, Peter; Barwell, Julian; Bernstein, Jonine L.; Bobolis, Kristie; Borg, Åke; Blomqvist, Carl; Claes, Kathleen B.M.; Concannon, Patrick; Cuggia, Adeline; Culver, Julie O.; Damiola, Francesca; De Pauw, Antoine; Diez, Orland; Dolinsky, Jill S.; Domchek, Susan M.; Engel, Christoph; Evans, D. Gareth; Fostira, Florentia; Garber, Judy; Golmard, Lisa; Goode, Ellen L.; Gruber, Stephen B.; Hahnen, Eric; Hake, Christopher; Heikkinen, Tuomas; Hurley, Judith E.; Janavicius, Ramunas; Kleibl, Zdenek; Kleiblova, Petra; Konstantopoulou, Irene; Kvist, Anders; Laduca, Holly; Lee, Ann S.G.; Lesueur, Fabienne; Maher, Eamonn R.; Mannermaa, Arto; Manoukian, Siranoush; McFarland, Rachel; McKinnon, Wendy; Meindl, Alfons; Metcalfe, Kelly; Taib, Nur Aishah Mohd; Moilanen, Jukka; Nathanson, Katherine L.; Neuhausen, Susan; Ng, Pei Sze; Nguyen-Dumont, Tu; Nielsen, Sarah M.; Obermair, Florian; Offit, Kenneth; Olopade, Olufunmilayo I.; Ottini, Laura; Penkert, Judith; Pylkäs, Katri; Radice, Paolo; Ramus, Susan J.; Rudaitis, Vilius; Side, Lucy; Silva-Smith, Rachel; Silvestri, Valentina; Skytte, Anne Bine; Slavin, Thomas; Soukupova, Jana; Tondini, Carlo; Trainer, Alison H.; Unzeitig, Gary; Usha, Lydia; Van Overeem Hansen, Thomas; Whitworth, James; Wood, Marie; Yip, Cheng Har; Yoon, Sook Yee; Yussuf, Amal; Zogopoulos, George; Goldgar, David; Hopper, John L.; Chenevix-Trench, Georgia; Pharoah, Paul; George, Sophia H.L.; Balmaña, Judith; Houdayer, Claude; James, Paul; El-Haffaf, Zaki; Ehrencrona, Hans; Janatova, Marketa; Peterlongo, Paolo; Nevanlinna, Heli; Schmutzler, Rita; Teo, Soo Hwang; Robson, Mark; Pal, Tuya; Couch, Fergus; Weitzel, Jeffrey N.; Elliott, Aaron; Southey, Melissa; Winqvist, Robert; Easton, Douglas F.; Foulkes, William D.; Antoniou, Antonis C.; Tischkowitz, Marc.
In: Journal of Clinical Oncology, Vol. 38, No. 7, 01.03.2020, p. 674-685.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Cancer risks associated with germline PALB2 pathogenic variants
T2 - An international study of 524 families
AU - Yang, Xin
AU - Leslie, Goska
AU - Doroszuk, Alicja
AU - Schneider, Sandra
AU - Allen, Jamie
AU - Decker, Brennan
AU - Dunning, Alison M.
AU - Redman, James
AU - Scarth, James
AU - Plaskocinska, Inga
AU - Luccarini, Craig
AU - Shah, Mitul
AU - Pooley, Karen
AU - Dorling, Leila
AU - Leei, Andrew
AU - Adank, Muriel A.
AU - Adlard, Julian
AU - Aittomäki, Kristiina
AU - Andrulis, Irene L.
AU - Ang, Peter
AU - Barwell, Julian
AU - Bernstein, Jonine L.
AU - Bobolis, Kristie
AU - Borg, Åke
AU - Blomqvist, Carl
AU - Claes, Kathleen B.M.
AU - Concannon, Patrick
AU - Cuggia, Adeline
AU - Culver, Julie O.
AU - Damiola, Francesca
AU - De Pauw, Antoine
AU - Diez, Orland
AU - Dolinsky, Jill S.
AU - Domchek, Susan M.
AU - Engel, Christoph
AU - Evans, D. Gareth
AU - Fostira, Florentia
AU - Garber, Judy
AU - Golmard, Lisa
AU - Goode, Ellen L.
AU - Gruber, Stephen B.
AU - Hahnen, Eric
AU - Hake, Christopher
AU - Heikkinen, Tuomas
AU - Hurley, Judith E.
AU - Janavicius, Ramunas
AU - Kleibl, Zdenek
AU - Kleiblova, Petra
AU - Konstantopoulou, Irene
AU - Kvist, Anders
AU - Laduca, Holly
AU - Lee, Ann S.G.
AU - Lesueur, Fabienne
AU - Maher, Eamonn R.
AU - Mannermaa, Arto
AU - Manoukian, Siranoush
AU - McFarland, Rachel
AU - McKinnon, Wendy
AU - Meindl, Alfons
AU - Metcalfe, Kelly
AU - Taib, Nur Aishah Mohd
AU - Moilanen, Jukka
AU - Nathanson, Katherine L.
AU - Neuhausen, Susan
AU - Ng, Pei Sze
AU - Nguyen-Dumont, Tu
AU - Nielsen, Sarah M.
AU - Obermair, Florian
AU - Offit, Kenneth
AU - Olopade, Olufunmilayo I.
AU - Ottini, Laura
AU - Penkert, Judith
AU - Pylkäs, Katri
AU - Radice, Paolo
AU - Ramus, Susan J.
AU - Rudaitis, Vilius
AU - Side, Lucy
AU - Silva-Smith, Rachel
AU - Silvestri, Valentina
AU - Skytte, Anne Bine
AU - Slavin, Thomas
AU - Soukupova, Jana
AU - Tondini, Carlo
AU - Trainer, Alison H.
AU - Unzeitig, Gary
AU - Usha, Lydia
AU - Van Overeem Hansen, Thomas
AU - Whitworth, James
AU - Wood, Marie
AU - Yip, Cheng Har
AU - Yoon, Sook Yee
AU - Yussuf, Amal
AU - Zogopoulos, George
AU - Goldgar, David
AU - Hopper, John L.
AU - Chenevix-Trench, Georgia
AU - Pharoah, Paul
AU - George, Sophia H.L.
AU - Balmaña, Judith
AU - Houdayer, Claude
AU - James, Paul
AU - El-Haffaf, Zaki
AU - Ehrencrona, Hans
AU - Janatova, Marketa
AU - Peterlongo, Paolo
AU - Nevanlinna, Heli
AU - Schmutzler, Rita
AU - Teo, Soo Hwang
AU - Robson, Mark
AU - Pal, Tuya
AU - Couch, Fergus
AU - Weitzel, Jeffrey N.
AU - Elliott, Aaron
AU - Southey, Melissa
AU - Winqvist, Robert
AU - Easton, Douglas F.
AU - Foulkes, William D.
AU - Antoniou, Antonis C.
AU - Tischkowitz, Marc
PY - 2020/3/1
Y1 - 2020/3/1
N2 - PURPOSE To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized. METHODS We analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes. RESULTS We found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 × 10-76), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 × 10-3), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 × 10-3), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 3 1022). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age (P for trend = 2.0 × 10-3). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies (P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer. CONCLUSION These results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer risk management of PALB2 PV carriers.
AB - PURPOSE To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized. METHODS We analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes. RESULTS We found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 × 10-76), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 × 10-3), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 × 10-3), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 3 1022). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age (P for trend = 2.0 × 10-3). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies (P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer. CONCLUSION These results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer risk management of PALB2 PV carriers.
UR - http://www.scopus.com/inward/record.url?scp=85080075709&partnerID=8YFLogxK
U2 - 10.1200/JCO.19.01907
DO - 10.1200/JCO.19.01907
M3 - Article
C2 - 31841383
AN - SCOPUS:85080075709
VL - 38
SP - 674
EP - 685
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 7
ER -